Baloxavir (CAS 1985605-59-1) Antiviral

Baloxavir (CAS 1985605-59-1) is a premium pharmaceutical API with powerful antiviral activity, specifically targeting influenza A and B viruses. As a novel cap-dependent endonuclease inhibitor, it blocks viral replication at an early stage, offering a rapid and effective mechanism to combat influenza infections. Its high purity (≥99%) and excellent molecular stability ensure reliable performance in pharmaceutical formulations.

This cutting-edge API caters to pharmaceutical manufacturers and research institutions developing next-generation antiviral medications. Unlike traditional neuraminidase inhibitors, Baloxavir demonstrates broader antiviral spectrum and longer-lasting efficacy, meeting the demand for advanced influenza treatments. It is compatible with oral dosage forms, enabling convenient administration and enhancing patient compliance—making it a valuable ingredient for innovative antiviral solutions.